Noxopharm Ltd has released a press release.
Appendix 4D and FY2025 Half Year Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- SOF-SKN passes required in vitro safety tests
- December 2024 Quarterly Activities Report and Appendix 4C
- Additional convertible note for long-term shareholder
- September 2024 Quarterly Activities report and Appendix 4C
- New funding from sophisticated investors
Later from Noxopharm
- March 2025 Quarterly Activities Report and Appendix 4C
- New funds from Nyrada share sales
- Green light for HERACLES clinical trial
- Promising Sofra results from overseas company
- First SOF-SKN dose in HERACLES clinical trial
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm